- Annovis Bio Receives FDA Approval to Transition to New Crystal Form of Buntanetap
- Annovis Bio Welcomes Four New Executives to Strengthen Leadership Team
- Annovis Bio Announces New Data from Phase III Parkinson’s Study Highlighting Improvements in Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognition after Treatment with Buntanetap
- Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
- Annovis Bio Files Patent for New Composition of Matter for Buntanetap
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Discuss Parkinson’s Disease Data
- Annovis Bio Highlights New Alzheimer’s Data at the Alzheimer’s Association International Conference® 2024
- Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
- Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
- Annovis Announces New Publication in a Peer-Reviewed Journal
More ▼
Key statistics
On Tuesday, Annovis Bio Inc (ANVS:NYQ) closed at 10.65, 135.10% above the 52 week low of 4.53 set on Jul 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.72 |
---|---|
High | 11.11 |
Low | 10.50 |
Bid | 10.29 |
Offer | 10.60 |
Previous close | 10.65 |
Average volume | 942.51k |
---|---|
Shares outstanding | 11.17m |
Free float | 8.36m |
P/E (TTM) | -- |
Market cap | 118.98m USD |
EPS (TTM) | -5.04 USD |
Data delayed at least 15 minutes, as of Jul 23 2024 21:10 BST.
More ▼